EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Tolerability of Diquas LX on tear film and meibomian glands findings in a real clinical scenario

Reiko Arita iD, Shima Fukuoka iD, Minako Kaido

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0305020 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Reiko Arita und 2 weiteren Autor:innen. Beteiligte Einrichtung: Itoh Clinic, Saitama, Japan. Hauptthemen laut MEDLINE: Meibomian Glands, Tears, Ophthalmic Solutions, Dry Eye Syndromes. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Long-acting diquafosol ophthalmic solution (DQS-LX) has significant advantages regarding patient adherence owing to the reduced frequency of required eye drops; however, some patients prefer conventional diquafosol ophthalmic solution (DQS) over DQS-LX. Herein, to clarify the characteristics of patients according to their preference for ophthalmic solutions, dry eye (DE) and meibomian gland (MG) findings were retrospectively investigated. This study enrolled 341 patients with DE (mean age, 62.1 ± 11.7 years) treated at the Itoh Clinic between November 8, 2022, and July 31, 2023, who switched from DQS to DQS-LX. Patients were divided into two groups: those who continued DQS-LX administration (DQS-LX group) and those who wished to revert to conventional DQS (DQS group). Data regarding subjective symptoms assessed using the Standard Patient Evaluation of Eye Dryness (SPEED) questionnaire, tear film breakup time (BUT), tear meniscus height (TMH), corneal and conjunctival fluorescein staining (CFS), conjunctival hyperemia/papilla, meiboscore, plugging, vascularity, meibum grade, and Schirmer’s score at the time of DQS-LX switch were evaluated. Of the 341 patients, 31 (9.1%) wished to revert to conventional DQS. In total, 16 eyes of 16 patients in the DQS group and 32 eyes of 32 patients in the DQS-LX group—for whom complete data were available—were included in the analysis. The DQS-LX group had higher SPEED scores, lower TMHs ( P < 0.001, respectively), shorter FBUTs, greater CFS findings, larger meibum grades, lower Schirmer scores, and more pluggings compared with the DQS group ( P = 0.005, 0.001, 0.001, 0.046, 0.003, respectively). Meiboscores and vascularity did not differ significantly between the two groups ( P = 0.73 and 0.39, respectively). In conclusion, patients with low tear film volume and DE complicated by moderate or severe meibomian gland dysfunction (MGD) preferred DQS-LX, while those with allergic findings preferred conventional DQS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Meibomian GlandsTearsOphthalmic SolutionsDry Eye SyndromesUracil NucleotidesPolyphosphatesHumansMiddle AgedFemaleMaleAgedRetrospective StudiesMeibomian Gland Dysfunction

Substanzen

Ophthalmic SolutionsdiquafosolUracil NucleotidesPolyphosphates

Autor:innen und Institutionen

  • Itoh Clinic, Saitama, Japan.
  • Lid and Meibomian Gland Working Group, Saitama, Japan.
  • Omiya Hamada Eye Clinic, Saitama, Japan.
  • Wada Eye Clinic, Chiba, Japan.

ORCID-Profile: Reiko Arita, Shima Fukuoka

Zitieren

APA

Arita, R., Fukuoka, S., & Kaido, M. (2024). Tolerability of Diquas LX on tear film and meibomian glands findings in a real clinical scenario. PLOS ONE. https://doi.org/10.1371/journal.pone.0305020

Vancouver

Arita R, Fukuoka S, Kaido M. Tolerability of Diquas LX on tear film and meibomian glands findings in a real clinical scenario. PLOS ONE. 2024. doi:10.1371/journal.pone.0305020

BibTeX
@article{Arita2024,
  author = {Arita, Reiko and Fukuoka, Shima and Kaido, Minako},
  title = {Tolerability of Diquas LX on tear film and meibomian glands findings in a real clinical scenario},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0305020}
}
Kostenlos starten →